Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 6/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.31 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10607618 | 0.92 | CA1 (0.41) | CA1CA2TSHRHPGDCA9 | |
| SCHEMBL10738821 | 0.92 | CA1 (0.41) | CA1CA2TSHRHPGDCA9 | |
| SCHEMBL5145331 | 0.92 | CA1 (0.41) | CA1CA2TSHRHPGDCA9 | |
| SCHEMBL78605 | 0.89 | CA1 (0.43) | CA1CA2TSHRHPGDCA9 | |
| SCHEMBL9225312 | 0.89 | CA1 (0.43) | CA1CA2TSHRHPGDCA9 | |
| SCHEMBL4811160 | 0.89 | CA1 (0.43) | CA1CA2TSHRHPGDCA9 | |
| SCHEMBL6405689 | 0.89 | CA1 (0.43) | CA1CA2TSHRHPGDCA9 | |
| SCHEMBL1123875 | 0.82 | — | — | |
| SCHEMBL3853831 | 0.81 | CA1 (0.33) | CA1CA2 | |
| SCHEMBL8911241 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 828 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3632441-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DAY ONE BIOPHARMACEUTICALS INC (US) | 2024-07-17 | — | — | EP | disclosed |
| EP-3782986-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-10 | — | — | EP | disclosed |
| US-20240217957-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-07-04 | — | — | US | disclosed |
| US-12024505-B2 | Heterocyclic compounds useful as modulators of acetylcholine receptors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-07-02 | — | — | US | disclosed |
| WO-2024135652-A1 | REISSERT-HENZE REACTION USING PHOSPHONIC ACID ANHYDRIDE AS ACTIVATOR | ＡＧＣ株式会社 | 2024-06-27 | — | — | WO | disclosed |
| US-12012419-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-18 | — | — | US | disclosed |
| WO-2024116086-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-06 | — | — | WO | disclosed |
| US-20240174677-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-05-30 | — | — | US | disclosed |
| US-20240174610-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-05-30 | — | — | US | disclosed |
| EP-4034257-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-05-22 | — | — | EP | disclosed |
| EP-0517262-A1 | Trifluorothymidine derivatives, process for producing the same and anti-cancer agent containing the same | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1992-12-09 | — | — | EP | disclosed |
| US-5158943-A | Osteoporosis | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-10-27 | — | — | US | disclosed |
| EP-0509559-A2 | Alpha-unsaturated amines, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-10-21 | — | — | EP | disclosed |
| EP-0496106-A1 | Stable agrochemical compositions | Takeda Chemical Industries, Ltd. (JP) | 1992-07-29 | — | — | EP | disclosed |
| EP-0460488-A1 | Sulfur-containing heterocyclic compounds | Takeda Chemical Industries, Ltd. (JP) | 1991-12-11 | — | — | EP | disclosed |
| US-5071841-A | For prevention of bone reabsorption | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-12-10 | — | — | US | disclosed |
| EP-0376197-A1 | Sulfur-containing heterocyclic compounds | Takeda Chemical Industries, Ltd. (JP) | 1990-07-04 | — | — | EP | disclosed |
| EP-0302389-A2 | Alpha-unsaturated amines, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1989-02-08 | — | — | EP | disclosed |
| US-4119780-A | 2(Isopropyldithio)benzimidazole | MONSANTO COMPANY (US) | 1978-10-10 | — | — | US | disclosed |
| US-4006155-A | Method for preparation of phosphorus polysulfides | MONSANTO COMPANY (US) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174677-A1 | HETEROCYCLIC COMPOUND | HCRTR2, HCRTR1, NPY2R | CYP3A4 1461/4885ADRB2 115/4885ADRB1 235/4885 |
| US-20240174610-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, NTSR2 | CYP3A4 2470/4885ADRB2 120/4885ADRB1 199/4885 |
| US-20240217957-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, NPY2R | CYP3A4 1004/4885ADRB2 114/4885ADRB1 237/4885 |
| US-12024505-B2 | Heterocyclic compounds useful as modulators of acetylcholine receptors | CHRM3, CHRNA1, CHRM5 | CYP3A4 1074/4885ADRB2 42/4885ADRB1 36/4885 |
| US-12012419-B2 | Heterocyclic compound | SLC10A2, ALPI, SLC10A1 | CYP3A4 793/4885ADRB2 433/4885ADRB1 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.